# Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

> **NCT01843387** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mesoblast, Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Diabetic Nephropathy
- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** Mesenchymal Precursor Cells (MPCs)
- **BIOLOGICAL:** Mesenchymal Precursor Cells (MPCs)

## Key facts

- **NCT ID:** NCT01843387
- **Lead sponsor:** Mesoblast, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-09
- **Final completion:** 2015-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843387, "Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01843387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*